{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:07:43Z","timestamp":1789592863378,"version":"build-2803163510"},"reference-count":63,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T00:00:00Z","timestamp":1663632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1128\/ASMCopyrightv2"},{"start":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T00:00:00Z","timestamp":1663632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"HHS | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201800039C"],"award-info":[{"award-number":["HHSN272201800039C"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2022,9,20]]},"abstract":"<jats:p>Tuberculosis (TB) remains a major cause of morbidity and mortality, particularly in low- and middle-income countries where access to health care workers, cold-chain storage, and sterile water sources may be limited. Inhaled drug delivery is a promising alternative to systemic delivery of antimycobacterial drugs, as it enables rapid achievement of high infection-site drug concentrations.<\/jats:p>","DOI":"10.1128\/aac.00186-22","type":"journal-article","created":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T13:01:09Z","timestamp":1660050069000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":14,"title":["Respirable Clofazimine Particles Produced by Air Jet Milling Technique Are Efficacious in Treatment of BALB\/c Mice with Chronic Mycobacterium tuberculosis Infection"],"prefix":"10.1128","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5456-5427","authenticated-orcid":true,"given":"Ashlee D.","family":"Brunaugh","sequence":"first","affiliation":[{"name":"Via Therapeutics, LLC, Austin, Texas, USA"},{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Walz","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology &amp; Pathology, Colorado State University, Fort Collins, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Warnken","sequence":"additional","affiliation":[{"name":"Via Therapeutics, LLC, Austin, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camron","family":"Pearce","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology &amp; Pathology, Colorado State University, Fort Collins, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Munoz Gutierrez","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology &amp; Pathology, Colorado State University, Fort Collins, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Koleng","sequence":"additional","affiliation":[{"name":"Via Therapeutics, LLC, Austin, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh D. C.","family":"Smyth","sequence":"additional","affiliation":[{"name":"Via Therapeutics, LLC, Austin, Texas, USA"},{"name":"Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, University of Texas, Austin, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Gonzalez-Juarrero","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology &amp; Pathology, Colorado State University, Fort Collins, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","unstructured":"World Health Organization. 2019. Global tuberculosis report 2019. World Health Organization Geneva Switzerland."},{"key":"e_1_3_3_3_2","volume-title":"WHO consolidated guidelines on drug-resistant tuberculosis treatment","author":"World Health Organization","year":"2019","unstructured":"World Health Organization. 2019. WHO consolidated guidelines on drug-resistant tuberculosis treatment. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0307-290"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60359-9"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2011.10.011"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1086\/518663"},{"key":"e_1_3_3_8_2","unstructured":"Anonymous. 2019. Lamprene [package insert]. Novartis Pharmaceuticals Corporation East Hanover New Jersey."},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/1791013a0"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr444"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw426"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.3109\/03602539508994208"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1021\/cg301463z"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00037-14"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01731-12"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.09.031"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.5935\/0305-7518.19830039"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1980.tb05697.x"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw004"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.3109\/03602539508994208"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00260-15"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198916020-00002"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-21271-7"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.200501"},{"key":"e_1_3_3_25_2","first-page":"1083","article-title":"Chemotherapeutic activity of clofazimine and its analogues against Mycobacterium tuberculosis: in vitro, intracellular, and in vivo studies","volume":"151","author":"Jagannath C","year":"1995","unstructured":"Jagannath C, Reddy MV, Kailasam S, O'Sullivan J, Gangadharam P. 1995. Chemotherapeutic activity of clofazimine and its analogues against Mycobacterium tuberculosis: in vitro, intracellular, and in vivo studies. Am J Respir Crit Care Med 151:1083\u20131086.","journal-title":"Am J Respir Crit Care Med"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201001-0077OC"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ027"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0047494"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.5b00035"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00265-16"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01897-12"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2019.05.013"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.7b00690"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1021\/mp200101b"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.22706"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2010.08.005"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2018.08.001"},{"key":"e_1_3_3_38_2","unstructured":"WHO Prequalification Team. 2021. Notes on the Design of Bioequivalence Study: clofazimine. World Health Organization Geneva Switzerland."},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw417"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14010015"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.6.3128"},{"key":"e_1_3_3_42_2","first-page":"479","article-title":"The antileprosy agent B.663 (Clofazimine) and the reticuloendothelial system","volume":"39","author":"Conalty ML","year":"1971","unstructured":"Conalty ML, Barry VC, Jina AG. 1971. The antileprosy agent B.663 (Clofazimine) and the reticuloendothelial system. Int J Lepr Other Mycobact Dis 39:479\u2013492.","journal-title":"Int J Lepr Other Mycobact Dis"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01168"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1006\/rtph.1995.1017"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-323-07307-3.10036-9"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12217"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901089"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0017550"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02565-14"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1601-0825.2005.01217.x"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.29.1923"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.14356\/kona.2019008"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/27.6.377"},{"key":"e_1_3_3_54_2","first-page":"1084","volume-title":"United States Pharmacopeia","author":"Anonymous","year":"2021","unstructured":"Anonymous. 2021. Clofazimine, p 1084, In United States Pharmacopeia, vol USP43-NF38. United States Pharmacopeial Convention, North Bethesda, Maryland."},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-64235-6"},{"key":"e_1_3_3_56_2","volume-title":"Inhalation and nasal drug products: aerosols, sprays, and powders \u2014performance quality tests, United States pharmacopeia","author":"Anonymous","year":"2019","unstructured":"Anonymous. 2019. Inhalation and nasal drug products: aerosols, sprays, and powders \u2014performance quality tests, United States pharmacopeia, vol 42. United States Pharmacopeial Convention, Inc., Rockville, MD."},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-010-0070-5"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.14227\/DT170210P6"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2020.05.004"},{"key":"e_1_3_3_60_2","unstructured":"R Development Core Team. 2019. R: a language and environment for statistical computing R Foundation for Statistical Computing Vienna Austria. https:\/\/www.R-project.org\/."},{"key":"e_1_3_3_61_2","unstructured":"Harrold J. 2021. ubiquity: PKPD PBPK and systems pharmacology modeling tools v2.0.0. https:\/\/ubiquity.tools\/rworkflow."},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00177-16"},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201304-0753OC"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2019.06.002"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00186-22","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00186-22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T13:16:40Z","timestamp":1663679800000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.00186-22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,20]]},"references-count":63,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9,20]]}},"alternative-id":["10.1128\/aac.00186-22"],"URL":"https:\/\/doi.org\/10.1128\/aac.00186-22","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,20]]},"assertion":[{"value":"2022-02-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00186-22"}}